Engineered mutants improve thermostability in transglutaminase, suggesting potential for industrial use.
The industrial application of Streptomyces mobaraensis transglutaminase (smTG) is limited by its poor thermostability. To enhance its stability, we engineered a thermostable mutant, FRAPD-TGm2A1, using helix-corner design. Following the introduction of the known stabilizing mutation Y34W, Cartesian_ddG was used to virtually screen 56 helix-corner residue sites, from which 20 top-ranking mutations with reduced folding free energy were experimentally tested. Four single mutations (G157N, G157Q, G157W, and A160P) that notably improved thermostability were combined, generating FRAPD-TGm2A-Y34W-G157Q-A160P (FRAPD-TGm2A1) with the highest thermal stability. Compared with FRAPD-TGm2A, the half-life of FRAPD-TGm2A1 increased by 44.46% at 60 °C (176.32 min), 44.01% at 65 °C (14.66 min), and 108.21% at 70 °C (2.79 min), while the melting temperature rose by 1.81 °C. FRAPD-TGm2A1 also efficiently cross-linked β-casein at 75 °C. Importantly, FRAPD-TGm2A1 was successfully expressed in S. mobaraensis, exhibiting a half-life of 160.03 min at 60 °C, far exceeding that of wild-type (<2 min) and demonstrating promising potential for industrial application.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: